Synthetic peptide
B7-33
An experimental biased RXFP1 agonist developed to reproduce selected vasodilatory and antifibrotic actions of relaxin.
Evidence confidence
Human
Not yet assessed
Trust Engine review pending.
Animal
2/5
Some animal evidence
1 citation
Mechanistic
Not yet assessed
Trust Engine review pending — see editorial links below.
Editorial evidence links exist, but this category has not yet completed Trust Engine assessment.
Safety
Not yet assessed
Trust Engine review pending.
Claimed uses
- Insufficient
Mechanisms
- not-yet-documented
- Relaxin family peptide receptor signalling
- Extracellular matrix remodelling
Safety notes
Human pharmacokinetics, immunogenicity, reproductive effects and long-term cardiovascular safety are unknown.
Regulation
- Not approved as a medicine. Research use does not establish safety for self-administration.
References
Last reviewed
12 July 2026